Neoadjuvant Therapy for Hepatocellular Carcinoma

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

(2022) Ghassan K. Abou-Alfa et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

(2022) Thomas U Marron et al.   Lancet Gastroenterology & Hepatology

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

(2021) Giacomo Bregni et al.   ACTA ONCOLOGICA

Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).

(2021) Mark Yarchoan et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma

(2021) Atsushi Oyama et al.   HEPATOLOGY RESEARCH

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

(2021) Larissa A. Korde et al.   JOURNAL OF CLINICAL ONCOLOGY

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

(2021) David J. Pinato et al.   BMC CANCER

Cabozantinib: An Evolving Therapy for Hepatocellular Carcinoma

(2021) Anthony B. El-Khoueiry et al.   CANCER TREATMENT REVIEWS

The Current Landscape of Clinical Trials for Systemic Treatment of HCC

(2021) Friedrich Foerster et al.   Cancers

Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options

(2021) Andreas Koulouris et al.   Journal of Hepatocellular Carcinoma

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

(2021) Alexander Bagaev et al.   CANCER CELL

Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma

(2021) Masahiro Ohira et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

(2021) Richard S. Finn et al.   CLINICAL CANCER RESEARCH

Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC

(2021) Chenhe Yi et al.   HEPATOLOGY

Immunomodulatory effects of lenvatinib plus anti‐PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma

(2021) Laura Torrens et al.   HEPATOLOGY

EGFR activation limits the response of liver cancer to lenvatinib

(2021) Haojie Jin et al.   NATURE

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

(2021) Hideki Iwamoto et al.   Cancers

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

(2021) Thomas Yau et al.   LANCET ONCOLOGY

Intratumoral heterogeneity and clonal evolution in liver cancer

(2020) Bojan Losic et al.   Nature Communications

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

(2020) Stephen P Hack et al.   Future Oncology

Immunotherapy as a downstaging therapy for liver transplantation

(2020) Birgit Schwacha‐Eipper et al.   HEPATOLOGY

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

(2020) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is Postoperative Adjuvant Transcatheter Arterial Infusion Therapy Effective for Patients with Hepatocellular Carcinoma who Underwent Hepatectomy? A Prospective Randomized Controlled Trial

(2020) Fumitoshi Hirokawa et al.   ANNALS OF SURGICAL ONCOLOGY

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

(2020) Michael S Lee et al.   LANCET ONCOLOGY

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

(2020) Vincenzo Mazzaferro et al.   LANCET ONCOLOGY

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

(2020) Di-Yang Xie et al.   Hepatobiliary Surgery and Nutrition

Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma

(2020) Qiaolin Li et al.   CANCER LETTERS

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

(2020) Vivek Subbiah et al.   LANCET ONCOLOGY

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

(2020) Hsiang-chi Tseng et al.   Nature Communications

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

(2020) Thomas Yau et al.   JAMA Oncology

Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review

(2020) Junwei Zhang et al.   Annals of Translational Medicine

Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma

(2020) Yan Zhang et al.   World Journal of Gastrointestinal Surgery

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma

(2020) Yunfan Sun et al.   CELL

Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma

(2020) David J. Pinato et al.   HEPATOLOGY

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

(2019) Ying Jiang et al.   NATURE

Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes

(2019) Ruidong Xue et al.   CANCER CELL

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

(2019) Lorenza Rimassa et al.   CANCER TREATMENT REVIEWS

A Positive Feedback Loop Between Cancer Stem‐Like Cells and Tumor‐Associated Neutrophils Controls Hepatocellular Carcinoma Progression

(2019) Shao‐Lai Zhou et al.   HEPATOLOGY

Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma

(2019) Ismail Labgaa et al.   HPB

A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation

(2019) Malin Sternby Eilard et al.   BMC CANCER

Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment

(2019) Sarah Berhane et al.   BRITISH JOURNAL OF CANCER

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas

(2019) Qi Zhang et al.   GUT

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study

(2019) Xubiao Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma

(2019) Ahmed Omar Kaseb et al.   Cancer Immunology Research

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

(2019) M. Moehler et al.   OncoImmunology

Fatal Hepatic Necrosis after Nivolumab as a Bridge to Liver Transplant for HCC – Are Checkpoint Inhibitors Safe for the Pre‐Transplant Patient?

(2019) Mina F. Nordness et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer

(2019) Li Liu et al.   CLINICAL CANCER RESEARCH

Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas

(2019) Xiaofan Ding et al.   GASTROENTEROLOGY

Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis

(2019) Chao Li et al.   Hepatology International

The outcome of the HCC patients underwent ALPPS

(2019) Chihan Peng et al.   MEDICINE

Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A

(2019) Beom-Hui Lee et al.   World Journal of Surgical Oncology

Eradication of Hepatocellular Carcinoma by NKG2D-Specific CAR-T Cells

(2019) Bin Sun et al.   Cancer Immunology Research

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma

(2019) Qiang Gao et al.   CELL

Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma

(2019) Qiming Zhang et al.   CELL

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach

(2019) Guohong Han et al.   HEPATOLOGY

Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging

(2019) Breno Boueri Affonso et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)

(2019) Shuqun Cheng et al.   Liver Cancer

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches

(2019) Maria Tagliamonte et al.   CANCER LETTERS

Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma

(2019) Liang-qing Dong et al.   JOURNAL OF HEPATOLOGY

Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome

(2019) Dan Liu et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Tumour evolution in hepatocellular carcinoma

(2019) Amanda J. Craig et al.   Nature Reviews Gastroenterology & Hepatology

Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma

(2018) Huapeng Lin et al.   ANZ JOURNAL OF SURGERY

Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing

(2018) Meng Duan et al.   CELL RESEARCH

Unknown

(2018)   Experimental and Clinical Transplantation

How to select the appropriate “neoadjuvant therapy” for hepatocellular carcinoma

(2018) Ken Liu et al.   EXPERT OPINION ON PHARMACOTHERAPY

Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification

(2018) Yutaka Kurebayashi et al.   HEPATOLOGY

Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma

(2018) Hongping Zheng et al.   HEPATOLOGY

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

(2018) Pierce K.H. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion

(2018) Carlo Spreafico et al.   JOURNAL OF HEPATOLOGY

Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma

(2018) Liang-Qing Dong et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

The immunology of hepatocellular carcinoma

(2018) Marc Ringelhan et al.   NATURE IMMUNOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study

(2018) Mégane Lemaire et al.   HPB

Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation

(2018) Feng Xue et al.   Oncology Letters

Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

(2018) Jae Uk Chong et al.   ANNALS OF SURGICAL ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma

(2018) Long-Zi Liu et al.   HEPATOLOGY

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

(2018) Valerie W. Rusch et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic variation in 3,010 diverse accessions of Asian cultivated rice

(2018) Wensheng Wang et al.   NATURE

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence

(2018) Jean-Luc Raoul et al.   CANCER TREATMENT REVIEWS

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

(2018) Jing Liu et al.   OncoImmunology

Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis

(2017) Laura Kulik et al.   HEPATOLOGY

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

(2017) Austin G. Duffy et al.   JOURNAL OF HEPATOLOGY

PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination

(2017) Arash Memarnejadian et al.   JOURNAL OF IMMUNOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

(2017) Valérie Vilgrain et al.   LANCET ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

(2017) Rui-hua Xu et al.   NATURE MATERIALS

Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data

(2017) Sheng-Long Ye et al.   TUMOR BIOLOGY

Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study

(2017) Michinori Hamaoka et al.   International Journal of Surgery

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

(2017) Andrew X. Zhu et al.   JAMA Oncology

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

(2017) et al.   JAMA Oncology

Immuno-thermal ablations – boosting the anticancer immune response

(2017) Ryan Slovak et al.   Journal for ImmunoTherapy of Cancer

Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies

(2016) Renske J. E. van den Bijgaart et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma

(2016) Riad Salem et al.   GASTROENTEROLOGY

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC.

(2016) Mohamed Bouattour et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

(2016) Kenji Ikeda et al.   JOURNAL OF GASTROENTEROLOGY

90Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes

(2016) Robert J. Lewandowski et al.   JOURNAL OF SURGICAL ONCOLOGY

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

(2016) Naomi B Haas et al.   LANCET

Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?

(2016) Amol Mehta et al.   Gastroenterology Research and Practice

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

ALPPS for primary and secondary liver tumors

(2016) Giovanni Vennarecci et al.   International Journal of Surgery

Hepatocellular carcinoma

(2016) Josep M. Llovet et al.   Nature Reviews Disease Primers

Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy

(2015) Cheng Sun et al.   ACTA PHARMACOLOGICA SINICA

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

(2015) Katrin Hoffmann et al.   BMC CANCER

Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma

(2015) J.-C. Nault et al.   CLINICAL CANCER RESEARCH

Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria

(2015) Francis Y. Yao et al.   HEPATOLOGY

Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma

(2015) Ming-Lun Yeh et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis

(2014) Shicheng Su et al.   CANCER CELL

Management of hepatocellular carcinoma

(2014) P. Fitzmorris et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma

(2014) Won Hyeok Choe   WORLD JOURNAL OF GASTROENTEROLOGY

Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study

(2013) Louise Barbier et al.   ANNALS OF SURGICAL ONCOLOGY

Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?

(2013) Julien Edeline et al.   ANNALS OF SURGICAL ONCOLOGY

Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma

(2013) Shuhei Yoshida et al.   HEPATOLOGY

Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: A nationwide Taiwan database analysis of long-term outcome predictors

(2013) Hon-Yi Shi et al.   JOURNAL OF SURGICAL ONCOLOGY

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

(2013) Wan-Yee Lau et al.   ONCOLOGY

Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection

(2012) Yun-Fan Sun et al.   HEPATOLOGY

Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation

(2011) Alan W. Katz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?

(2011) Masato Fujiki et al.   LIVER INTERNATIONAL

Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant

(2011) Aimee E. Truesdale et al.   TRANSPLANT INTERNATIONAL

Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence

(2010) Lorenzo Andreana et al.   DIGESTIVE AND LIVER DISEASE

Morphologic features of advanced hepatocellular carcinoma as a predictor of downstaging and Liver Transplantation: An intention-to-treat analysis

(2010) Omar Barakat et al.   LIVER TRANSPLANTATION

Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma

(2010) Wakai   ONCOLOGY REPORTS

A Prospective, Randomized, Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular Carcinoma

(2009) Wei-Ping Zhou et al.   ANNALS OF SURGERY

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety

(2009) Alessandro Vitale et al.   HEPATOLOGY

The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes

(2009) King-Teh Lee et al.   JOURNAL OF SURGICAL ONCOLOGY

Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma

(2009) Terence C. Chua et al.   LIVER INTERNATIONAL

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis

(2008) Francis Y. Yao et al.   HEPATOLOGY

Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma

(2008) Koichi Obara et al.   Hepatology International

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE